Lawrence is a great town! And deciphera is RIGHT across the street from Free State Brewery.
I am going to need some help with this one. We are looking for a computational chemist to join the team here in Lawrence. Come be by colleague and help us design new medicines!
@chemjobber.bsky.social #chemjobs
www.smartrecruiters.com/DecipheraPha...
@chemjobber.bsky.social #chemjobs
www.smartrecruiters.com/DecipheraPha...
Director, Computational Chemistry
Job Description: The Role:We are seeking a talented, collaborative, and highly motivated individual who has experienced in Computational Chemistry. This role involves working closely with a multidisci...
www.smartrecruiters.com
April 4, 2025 at 2:58 PM
Lawrence is a great town! And deciphera is RIGHT across the street from Free State Brewery.
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
https://medcitynews.com/2025/02/ono-pharma-fda-approval-vimseltinib-romvimza-deciphera-tgct-csf1-rare-tumor/
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
Romvimza, a drug for treating tenosynovial giant cell tumor, was initially developed by Deciphera Pharmaceuticals. Last year, Ono Pharmaceutical acquired Deciphera to build up its oncology portfolio and expand its business prospects in the U.S. and Europe.
medcitynews.com
February 18, 2025 at 6:29 PM
Ono Pharma Drug Acquired in $2.4B Deal Wins FDA Approval for Treating Rare Type of Tumor
https://medcitynews.com/2025/02/ono-pharma-fda-approval-vimseltinib-romvimza-deciphera-tgct-csf1-rare-tumor/
Sarcoma Community Day is coming to Manchester! 💙
📍 Mercure Manchester Piccadilly
📅 Mon 15 Sept | 🕤 9:30am–4pm
Free event for adults with sarcoma and their loved ones. Talks, stories, support & more.
Book now: sarcoma.org.uk/community-da
Thanks to Deciphera for sponsoring!
📍 Mercure Manchester Piccadilly
📅 Mon 15 Sept | 🕤 9:30am–4pm
Free event for adults with sarcoma and their loved ones. Talks, stories, support & more.
Book now: sarcoma.org.uk/community-da
Thanks to Deciphera for sponsoring!
July 17, 2025 at 9:00 AM
Sarcoma Community Day is coming to Manchester! 💙
📍 Mercure Manchester Piccadilly
📅 Mon 15 Sept | 🕤 9:30am–4pm
Free event for adults with sarcoma and their loved ones. Talks, stories, support & more.
Book now: sarcoma.org.uk/community-da
Thanks to Deciphera for sponsoring!
📍 Mercure Manchester Piccadilly
📅 Mon 15 Sept | 🕤 9:30am–4pm
Free event for adults with sarcoma and their loved ones. Talks, stories, support & more.
Book now: sarcoma.org.uk/community-da
Thanks to Deciphera for sponsoring!
After Georgie was told her uterine leiomyosarcoma was incurable, she and her wife Adel became determined to help others affected by sarcoma.
Join them for #RareButReal Maidstone on 6 September at Mote Park. 💙
Visit rarebutreal.org.uk/
Supported by Deciphera Pharmaceuticals.
Join them for #RareButReal Maidstone on 6 September at Mote Park. 💙
Visit rarebutreal.org.uk/
Supported by Deciphera Pharmaceuticals.
August 26, 2026 at 10:00 AM
After Georgie was told her uterine leiomyosarcoma was incurable, she and her wife Adel became determined to help others affected by sarcoma.
Join them for #RareButReal Maidstone on 6 September at Mote Park. 💙
Visit rarebutreal.org.uk/
Supported by Deciphera Pharmaceuticals.
Join them for #RareButReal Maidstone on 6 September at Mote Park. 💙
Visit rarebutreal.org.uk/
Supported by Deciphera Pharmaceuticals.
“I feel so lucky to be alive, and I want to make a difference.”
After her leiomyosarcoma diagnosis, Jess began fundraising and is now helping organise Rare But Real Swansea.
📅 22 August, 11am
📍 Swansea Beach
🚶 5km or 10km
Sign up: sarcoma.org.uk/get-involved...
After her leiomyosarcoma diagnosis, Jess began fundraising and is now helping organise Rare But Real Swansea.
📅 22 August, 11am
📍 Swansea Beach
🚶 5km or 10km
Sign up: sarcoma.org.uk/get-involved...
August 3, 2026 at 9:01 AM
“I feel so lucky to be alive, and I want to make a difference.”
After her leiomyosarcoma diagnosis, Jess began fundraising and is now helping organise Rare But Real Swansea.
📅 22 August, 11am
📍 Swansea Beach
🚶 5km or 10km
Sign up: sarcoma.org.uk/get-involved...
After her leiomyosarcoma diagnosis, Jess began fundraising and is now helping organise Rare But Real Swansea.
📅 22 August, 11am
📍 Swansea Beach
🚶 5km or 10km
Sign up: sarcoma.org.uk/get-involved...
Throughout Sarcoma Awareness Month, we've celebrated the voices of people living with sarcoma around the world. That is strengthened when industry chooses to listen, engage with patient advocates, and work alongside the community.
Thank you to our valued partners for supporting that vision.
Thank you to our valued partners for supporting that vision.
July 30, 2026 at 1:00 PM
Throughout Sarcoma Awareness Month, we've celebrated the voices of people living with sarcoma around the world. That is strengthened when industry chooses to listen, engage with patient advocates, and work alongside the community.
Thank you to our valued partners for supporting that vision.
Thank you to our valued partners for supporting that vision.
Thank you to everyone who joined us at our Manchester Community Day.
We’re grateful to all the attendees, speakers, and facilitators who gave their time to connect, share and support the sarcoma community.
A special thank you to Deciphera for sponsoring the event and helping make it possible. 💙
We’re grateful to all the attendees, speakers, and facilitators who gave their time to connect, share and support the sarcoma community.
A special thank you to Deciphera for sponsoring the event and helping make it possible. 💙
September 19, 2025 at 10:00 AM
Thank you to everyone who joined us at our Manchester Community Day.
We’re grateful to all the attendees, speakers, and facilitators who gave their time to connect, share and support the sarcoma community.
A special thank you to Deciphera for sponsoring the event and helping make it possible. 💙
We’re grateful to all the attendees, speakers, and facilitators who gave their time to connect, share and support the sarcoma community.
A special thank you to Deciphera for sponsoring the event and helping make it possible. 💙
Just 2 weeks to go! 💙 We can’t wait to welcome everyone to our second Community Day in Manchester on Mon 15 Sept. Want to join the waiting list? Email supportline@sarcoma.org.uk
Thank you to Deciphera Pharmaceuticals for sponsoring this event!
Thank you to Deciphera Pharmaceuticals for sponsoring this event!
September 1, 2025 at 2:58 PM
Just 2 weeks to go! 💙 We can’t wait to welcome everyone to our second Community Day in Manchester on Mon 15 Sept. Want to join the waiting list? Email supportline@sarcoma.org.uk
Thank you to Deciphera Pharmaceuticals for sponsoring this event!
Thank you to Deciphera Pharmaceuticals for sponsoring this event!
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight
KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution…
KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution…
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight
KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma (Navire Pharma), Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, and others (Albany, USA) In 2024, the United States held nearly 70% of the KRAS inhibitors market across the 7MM, driven by a high burden of KRAS-mutated cancers, especially NSCLC, which accounts for 46% of such cases in the region.
www.pressreleasecc.com
July 10, 2025 at 11:21 AM
KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight
KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution…
KRAS Inhibitors Drugs Market KRAS Inhibitors companies working in the market are Novartis, Roche, Genentech, Verastem Oncology, Revolution…
#ROMVIMZA #Vimseltinib #TGCTtreatment #tenosynovialgiantcelltumour #EU #symptomatictenosynovialgiantcelltumour #TGCT #marketingauthorisation #TGCTtherapy #OnoPharmaceutical #Deciphera #phase3MOTIONstudy #Secondaryendpoints #tumourresponse #stiffness #qualityoflife
pharmatimes.com/news/europea...
pharmatimes.com/news/europea...
European Commission approves ROMVIMZA for TGCT treatment - PharmaTimes
Vimseltinib becomes first authorised therapy for tenosynovial giant cell tumour in the EU
pharmatimes.com
September 22, 2025 at 8:26 AM
#biopharmaceuticals #DecipheraPharmaceuticals #Romvimza #tenosynovialgiantcelltumours #TGCT #vimseltinib #FDAapprovel #Deciphera #raretumourtype #symptomatictenosynovialgiantcelltumours #tyrosinekinaseinhibitor #CSF1R #CSF1Rinhibitor #MOTIONclinicaltrial
pharmatimes.com/news/fda-app...
pharmatimes.com/news/fda-app...
FDA approves Deciphera’s Romvimza for rare tumour type - PharmaTimes
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations
pharmatimes.com
February 27, 2025 at 10:02 AM
Director, Computational Chemistry @ Deciphera Pharmaceuticals Job DescriptionWe are seeking a tal...
Origin | Interest | Match
Origin | Interest | Match
Director, Computational Chemistry at Deciphera Pharmaceuticals - Lawrence, KS, United States
Deciphera Pharmaceuticals is hiring for Full Time Director, Computational Chemistry - Lawrence, KS, United States, an executive-level AI/ML/Data Science role offering benefits such as 401(k) matching, career development, competitive pay, health care, medical leave, parental leave, salary bonus.
aijobs.net
June 7, 2025 at 5:55 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Thursday, June 18, 2026
By: Salong Debbarma on Thursday, June 18, 2026
First patient dosed in Deciphera’s Phase III INTREPID study
Deciphera Pharmaceuticals has dosed the first patient in its global pivotal Phase III INTREPID study, evaluating sapablursen for the treatment of PV.
www.clinicaltrialsarena.com
June 18, 2026 at 10:33 AM
Feed: "Clinical Trials Arena"
By: Salong Debbarma on Thursday, June 18, 2026
By: Salong Debbarma on Thursday, June 18, 2026
Avis relatif aux prix d’une spécialité pharmaceutique
En application de la convention entre le comité économique des produits de santé et la société DECIPHERA, les prix de la spécialité pharmaceutique visée ci-dessous sont fixés comme suit : N° CIP Présentation PFHT PPTTC 34009 302 436 4 0 QINLOCK…
En application de la convention entre le comité économique des produits de santé et la société DECIPHERA, les prix de la spécialité pharmaceutique visée ci-dessous sont fixés comme suit : N° CIP Présentation PFHT PPTTC 34009 302 436 4 0 QINLOCK…
Avis relatif aux prix d’une spécialité pharmaceutique
En application de la convention entre le comité économique des produits de santé et la société DECIPHERA, les prix de la spécialité pharmaceutique visée ci-dessous sont fixés comme suit : N° CIP Présentation PFHT PPTTC 34009 302 436 4 0 QINLOCK 50 mg (ripretinib), comprimés (B/90) (laboratoires DECIPHERA) 18 339,04 € 18 857,04 € Cette décision entre en vigueur à compter du quatrième jour suivant la publication au Journal officiel de la République française.
kohenavocats.fr
December 25, 2024 at 8:32 PM
Avis relatif aux prix d’une spécialité pharmaceutique
En application de la convention entre le comité économique des produits de santé et la société DECIPHERA, les prix de la spécialité pharmaceutique visée ci-dessous sont fixés comme suit : N° CIP Présentation PFHT PPTTC 34009 302 436 4 0 QINLOCK…
En application de la convention entre le comité économique des produits de santé et la société DECIPHERA, les prix de la spécialité pharmaceutique visée ci-dessous sont fixés comme suit : N° CIP Présentation PFHT PPTTC 34009 302 436 4 0 QINLOCK…
TuHURA Biosciences appoints Dr Bertrand Le Bourdonnec as head of drug discovery, early development and program management
*expert on opioid receptor biochemistry
*previously at HDAX Therapeutics & Deciphera Pharma
$HURA
finance.yahoo.com/news/tuhura-...
*expert on opioid receptor biochemistry
*previously at HDAX Therapeutics & Deciphera Pharma
$HURA
finance.yahoo.com/news/tuhura-...
TuHURA Biosciences, Inc. Appoints Dr. Bertrand Le Bourdonnec as Executive Vice President, Head of Drug Discovery, Early Development, and Program Management
TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced t...
finance.yahoo.com
April 7, 2025 at 1:20 PM
TuHURA Biosciences appoints Dr Bertrand Le Bourdonnec as head of drug discovery, early development and program management
*expert on opioid receptor biochemistry
*previously at HDAX Therapeutics & Deciphera Pharma
$HURA
finance.yahoo.com/news/tuhura-...
*expert on opioid receptor biochemistry
*previously at HDAX Therapeutics & Deciphera Pharma
$HURA
finance.yahoo.com/news/tuhura-...
